Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a popular Weight-Loss drug help—or Harm—Those with duchenne muscular dystrophy?

NCT ID NCT07642635

Not yet recruiting Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide (a GLP-1 drug used for weight loss) is safe for adolescents and young adults with Duchenne muscular dystrophy (DMD) who are also overweight or obese. The main concern is that the drug might reduce muscle mass, which is already weak in DMD. Participants will take either semaglutide or a placebo for 24 weeks, then all will receive semaglutide for another 40 weeks. The study monitors muscle mass, fat, heart and lung function, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide (Rybelsus)
What this could lead to
If safe, this could offer a weight-loss option for people with Duchenne muscular dystrophy who struggle with obesity, potentially improving heart and metabolic health.
What could go wrong
This is an early-phase trial with only 30 participants. The main concern is that semaglutide might reduce muscle mass, which is already compromised in DMD. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY (DMD)

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.